2007   Nov, 13 Lupin gets new Pharmaceutical Research Head   Oct, 24 Lupin FY 2007-08 Q2 Consolidated Net Profit up 46% to Rs. 756 mn   Oct, 10 Lupin acquires in Japan   Sept, 27 Lupin acquires pharmaceutical business of Rubamin   Sept, 12 Lupin wins Ramipril product patent challenge at Federal Circuit   August, 13 Lupin appoints Ramesh Swaminathan as President Finance & Planning   July, 31 Lupin Receives “Best New Manufacturer of the Year” Award fromAmerisourceBergen   July, 19 Lupin FY 2007-08 Q1 Net Profit up 55% to Rs. 784 mn   July, 18 Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it’s herbal Psoriasis NCE   July, 17 Lupin Receives US FDA Approval for Amlodipine   July, 2 Lupin gets MHRA Approval for Lisinopril in UK   June, 14 Lupin receives Final FDA Approval for Trandolapril   May, 31 Lupin Receives US FDA Approval for Cefadroxil Capsules Lupin and Symbiotec decide not to pursue their MoU   May, 21 Lupin receives tentative US FDA Approval for Ziprasidone   May, 15 Lupin Receives US FDA Approval for Simvastatin Tablets   April, 27 DST and Lupin join hands over Migraine and Psoriasis   April, 12 Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension   March, 13 Lupin gets Marketing Approval for Cefpodoxime Proxetil in France   Feb, 20 Lupin sells Intellectual Property on Perindopril to Servier   Feb, 7 Lupin receives US FDA approval for Sertraline   Jan, 19 Lupin and Aspen decide not to pursue their MOU   Jan, 17 Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs.560 mn   Jan, 2 Lupin gets tentative US FDA approval for Sertraline